About David
David Chen is a Partner at Northline Ventures, where he leads seed and Series A investments at the intersection of machine learning and drug discovery. He has been on the founding board of seven AI-bio companies, two of which have gone public.
At Rounds he writes a monthly column from a board-seat perspective — how AI-bio rounds actually get priced, what term sheets look like in 2025, and why most lab-in-the-loop pitches fail diligence.
Before Northline, David was a computational biologist at the Everfield Research Center.
Highlights
- Founding board, 7 AI-bio companies (2 IPOs).
- a fictional venture-investing shortlist (2024).
- Published in a fictional research journal on foundation models for protein design.
Experience
- 2020 — PresentPartnerNorthline Ventures
Seed and Series A in machine learning for drug discovery.
- 2017 — 2020PrincipalStonepath Bio Ventures
- 2013 — 2017Computational BiologistEverfield Research Center
